Antineutrophil Cytoplasmic Antibody (ANCA) Test: Antineutrophil Cytoplasmic Antibody Testing for Vasculitis

antineutrophil cytoplasmic antibody Test: Antineutrophil Cytoplasmic Antibody Testing for Vasculitis — scientific infographic poster

Antineutrophil cytoplasmic antibodies (antineutrophil cytoplasmic antibody, ANCA) are autoantibodies directed against proteins stored in the primary granules of neutrophils and in monocyte lysosomes. The antineutrophil cytoplasmic antibody test is the cornerstone laboratory investigation for diagnosing antineutrophil cytoplasmic antibody-associated vasculitides (AAV) — a group of small- to medium-vessel inflammatory diseases that can cause rapidly progressive organ failure, particularly of the kidneys and lungs. Understanding the two major antineutrophil cytoplasmic antibody patterns and their corresponding antigens, and always confirming indirect immunofluorescence (IIF) results with antigen-specific immunoassays, is essential for accurate diagnosis and avoidance of false positives.

Table of Contents

  1. Overview — What Is the Antineutrophil Cytoplasmic Antibody Test?
  2. Testing Methodology: IIF and Antigen-Specific EIA
  3. Antineutrophil Cytoplasmic Antibody Patterns: c-ANCA vs. p-ANCA
  4. Antineutrophil Cytoplasmic Antibody-Associated Vasculitides
  5. Reference Ranges and Interpretation
  6. False Positives and Mimics
  7. Drug-Induced Antineutrophil Cytoplasmic Antibody Vasculitis
  8. Serial Antineutrophil Cytoplasmic Antibody Monitoring for Disease Activity
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Overview — What Is the Antineutrophil Cytoplasmic Antibody Test?

Antineutrophil cytoplasmic antibody were first described by Davies et al. in 1982 in patients with segmental necrotizing glomerulonephritis. The subsequent discovery that they react against specific neutrophil granule proteins — proteinase 3 (PR3) and myeloperoxidase (MPO) — transformed understanding of a previously enigmatic group of vasculitides. The 2017 revised International Chapel Hill Consensus Conference (CHCC) nomenclature recognizes antineutrophil cytoplasmic antibody-associated vasculitis as a distinct category of small-vessel vasculitis driven by these autoantibodies.

Antineutrophil cytoplasmic antibody are thought to be pathogenic rather than merely diagnostic markers. In vitro and animal model evidence indicates that antineutrophil cytoplasmic antibody (particularly anti-PR3 and anti-MPO) activate primed neutrophils, causing them to degranulate and release oxidants and proteases against vascular endothelium. This mechanism explains why antineutrophil cytoplasmic antibody vasculitis predominantly affects small vessels: neutrophils adhere to and damage the thin-walled capillaries and venules of the kidneys, lungs, sinuses, and skin.

The antineutrophil cytoplasmic antibody test is indicated in patients presenting with:

Back to Table of Contents

Testing Methodology: IIF and Antigen-Specific EIA

Antineutrophil cytoplasmic antibody testing employs a two-step strategy mandated by major international guidelines including the 2017 International Consensus Statement on antineutrophil cytoplasmic antibody Testing:

Step 1 — Indirect Immunofluorescence (IIF)

Patient serum is incubated on ethanol-fixed human neutrophil substrate slides. Fluorescence microscopy reveals one of several staining patterns:

IIF is sensitive but not specific. The 2017 consensus changed the recommended testing algorithm: antigen-specific EIA is now validated as a first-line test and should always be performed regardless of IIF result when antineutrophil cytoplasmic antibody vasculitis is clinically suspected.

Step 2 — Antigen-Specific Immunoassay (EIA/ELISA)

Anti-PR3 (proteinase 3) and anti-MPO (myeloperoxidase) ELISAs or multiplexed bead assays confirm and quantify the specific autoantibody. These tests provide:

The shift to high-sensitivity, high-specificity EIA platforms means that a negative IIF with a positive anti-PR3 or anti-MPO EIA should be taken seriously and not dismissed as a false positive. The 2017 consensus recommends that clinical laboratories report both IIF pattern and specific antigen reactivity together.

Back to Table of Contents

Antineutrophil Cytoplasmic Antibody Patterns: c-ANCA vs. p-ANCA

c-ANCA / Anti-PR3 Antibodies

Proteinase 3 (PR3) is a 29 kDa serine protease stored in neutrophil azurophilic (primary) granules. It plays roles in killing pathogens and in modulating inflammation through cleavage of cytokines. PR3 is constitutively expressed on the surface of neutrophils in antineutrophil cytoplasmic antibody vasculitis patients to a greater degree than in healthy individuals — a phenomenon called "membrane PR3 expression" that may predispose to antineutrophil cytoplasmic antibody-mediated neutrophil activation.

Anti-PR3 antibodies produce the classic c-ANCA pattern on IIF. They are strongly associated with granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis) — present in approximately 85–90% of generalized (active, multiorgan) GPA, and in a substantially smaller share of localized (upper respiratory only) GPA (see the sensitivity figures under Reference Ranges). Anti-PR3 titers tend to correlate more closely with disease activity than anti-MPO, and rising PR3-ANCA titers predict relapse more reliably.

p-ANCA / Anti-MPO Antibodies

Myeloperoxidase (MPO) is a 150 kDa heme-containing enzyme in neutrophil azurophilic granules. It catalyzes the production of hypochlorous acid (HOCl) from hydrogen peroxide and chloride — a potent antimicrobial mechanism that also causes bystander tissue damage in antineutrophil cytoplasmic antibody vasculitis. Anti-MPO antibodies produce the p-ANCA pattern on ethanol-fixed IIF.

Anti-MPO is the dominant antineutrophil cytoplasmic antibody specificity in microscopic polyangiitis (MPA) — present in approximately 75–80% of cases — and is also seen in eosinophilic GPA (formerly Churg-Strauss syndrome, approximately 30–40%), renal-limited antineutrophil cytoplasmic antibody vasculitis, and some drug-induced antineutrophil cytoplasmic antibody vasculitis cases. Anti-MPO-associated disease is more likely than anti-PR3 to manifest as renal-limited disease without granulomatous inflammation.

Back to Table of Contents

Antineutrophil Cytoplasmic Antibody-Associated Vasculitides

Granulomatosis with Polyangiitis (GPA)

Formerly Wegener's granulomatosis, GPA is characterized by necrotizing granulomatous inflammation of the upper and lower respiratory tract combined with pauci-immune necrotizing glomerulonephritis. The classic triad of sinusitis, pulmonary disease, and renal disease is present in only 15–20% of cases at presentation; localized upper airway disease may precede systemic manifestations by years. Hallmarks include saddle-nose deformity from cartilage destruction, subglottic stenosis, pulmonary nodules or cavities (which may be mistaken for malignancy or infection), and rapidly progressive GN. Anti-PR3 is positive in 85–90% of generalized GPA. Tissue biopsy showing necrotizing granulomatous vasculitis remains the gold standard for diagnosis when feasible.

Microscopic Polyangiitis (MPA)

MPA is a necrotizing small-vessel vasculitis with pauci-immune glomerulonephritis and frequent pulmonary capillaritis, but without the granulomatous inflammation that defines GPA. It is the most common cause of pulmonary-renal syndrome. Anti-MPO is present in 75–80% of MPA cases; PR3-ANCA occurs in a minority. MPA has a higher risk of ESRD than GPA and a lower relapse rate after remission induction.

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Formerly Churg-Strauss syndrome, EGPA combines asthma, peripheral blood eosinophilia (>10%), and necrotizing granulomatous vasculitis. Antineutrophil cytoplasmic antibody (predominantly anti-MPO) is positive in only 30–40% of EGPA — the antineutrophil cytoplasmic antibody-positive subset has more renal and peripheral nerve involvement (mononeuritis multiplex), while antineutrophil cytoplasmic antibody-negative EGPA tends to have more prominent cardiac and pulmonary eosinophilic infiltration. The FFS (Five-Factor Score) guides prognosis and treatment decisions.

Rapidly Progressive Glomerulonephritis (RPGN)

RPGN is a clinical syndrome — not a single disease — characterized by a rapid decline in glomerular filtration rate (GFR) over days to weeks, hematuria, red cell casts, and proteinuria. Approximately 70–80% of pauci-immune crescentic GN (the most common RPGN subtype) is antineutrophil cytoplasmic antibody-positive. When RPGN is suspected, antineutrophil cytoplasmic antibody testing should be obtained urgently alongside anti-GBM antibodies (to exclude Goodpasture syndrome), complement levels (to exclude immune complex disease), and kidney biopsy. In a patient with RPGN and strong clinical suspicion for AAV, treatment should not be delayed awaiting biopsy results — immunosuppression (pulse methylprednisolone + cyclophosphamide or rituximab) should begin as soon as other diagnoses are reasonably excluded.

Back to Table of Contents

Reference Ranges and Interpretation

There is no universal antineutrophil cytoplasmic antibody reference range because assay platforms, units, and cut-offs vary significantly between laboratories. Results should always be interpreted with the specific assay's reference interval in mind.

Sensitivity by disease state:

Paired bars of ANCA sensitivity by disease: anti-PR3 is positive in about 85–90% of generalized GPA, 50–65% of localized GPA, 5–10% of MPA and about 5% of EGPA, while anti-MPO is positive in 75–80% of MPA and 30–40% of EGPA; a strip along the bottom marks the 10–15% of ANCA-associated vasculitis that is seronegative, so a negative test does not exclude it. WHICH ANTIBODY, WHICH DISEASE share of patients who test positive, by disease state · cut-offs vary by laboratory anti-PR3 · c-ANCA anti-MPO · p-ANCA pale end = the upper end of a range 25%50% 75%100% generalized GPA localized GPA MPA EGPA active, multiorgan upper airway only microscopic polyangiitis eosinophilic GPA 85–90% 50–65% 5–10% ~5% 75–80% 30–40% anti-MPO: no figure given anti-MPO: no figure given all ANCA vasculitis ANCA-positive 10–15% seronegative THE SORT IS INCOMPLETE anti-PR3 points toward GPA 85–90% in generalized GPA, only 5–10% in MPA anti-MPO points toward MPA 75–80% in MPA, 30–40% in EGPA localized GPA is often missed anti-PR3 finds only ~50–65% of it a negative ANCA is not an all-clear 10–15% of AAV is seronegative; with strong clinical features, clinical and biopsy findings decide.

A negative antineutrophil cytoplasmic antibody does not exclude AAV in a patient with strong clinical features — particularly in localized GPA, early disease, or seronegative antineutrophil cytoplasmic antibody vasculitis (10–15% of AAV). Clinical and biopsy findings remain the gold standard.

Back to Table of Contents

False Positives and Mimics

The p-ANCA pattern on IIF is the greatest source of clinically misleading results because many conditions produce perinuclear staining without true MPO-directed autoantibodies:

Inflammatory Bowel Disease (IBD)

Both Crohn's disease and ulcerative colitis — particularly ulcerative colitis — are associated with a perinuclear antineutrophil cytoplasmic antibody pattern (sometimes called "atypical pANCA" or "xANCA"). These antibodies are directed against neutrophil lactoferrin, elastase, cathepsin G, and bactericidal/permeability-increasing protein rather than MPO. They are negative on anti-MPO EIA. The clinical significance of pANCA in inflammatory bowel disease is debated; it does not indicate vasculitis but may be a marker of disease extent in UC.

Autoimmune Hepatitis

Atypical pANCA is reported in 50–85% of autoimmune hepatitis type 1 (AIH-1, anti-smooth muscle antibody positive). As with inflammatory bowel disease-associated pANCA, the antigen is not MPO, and anti-MPO EIA is negative. The presence of elevated transaminases, gamma-globulin, and the characteristic autoantibody profile (ANA, ASMA) differentiates AIH from vasculitis.

Cocaine-Induced Midline Destructive Lesion (CIMDL)

Chronic cocaine inhalation causes midline facial destruction — saddle-nose deformity, septal perforation, palatal destruction — that mimics GPA clinically and radiographically. Crucially, cocaine is frequently adulterated with levamisole, a veterinary anthelmintic that induces anti-PR3-positive antineutrophil cytoplasmic antibody as well as anti-MPO-positive antineutrophil cytoplasmic antibody. A patient with midline facial destruction, systemic symptoms, and anti-PR3-positive antineutrophil cytoplasmic antibody who uses intranasal cocaine should be evaluated for CIMDL before diagnosing GPA. Clinical clues: agranulocytosis (levamisole effect), bilateral earlobe necrosis, positive cocaine metabolites in urine, anti-PR3-positive on EIA but with unusual antigen specificity (human neutrophil elastase) on detailed profiling.

Other Conditions

Back to Table of Contents

Drug-Induced Antineutrophil Cytoplasmic Antibody Vasculitis

A number of medications can induce antineutrophil cytoplasmic antibody production and frank antineutrophil cytoplasmic antibody vasculitis. Drug-induced antineutrophil cytoplasmic antibody vasculitis is a clinical diagnosis requiring medication exposure, antineutrophil cytoplasmic antibody positivity (typically anti-MPO), and evidence of vasculitis that resolves after drug discontinuation.

Propylthiouracil (PTU)

The antithyroid drug PTU carries the highest documented risk of antineutrophil cytoplasmic antibody induction. Up to 20–30% of patients on long-term PTU develop antineutrophil cytoplasmic antibody (predominantly anti-MPO, but also multi-ANCA with anti-PR3, anti-elastase, anti-lactoferrin). Approximately 1–5% develop frank vasculitis — glomerulonephritis, pulmonary infiltrates, cutaneous vasculitis. Methimazole induces antineutrophil cytoplasmic antibody vasculitis at far lower frequency.

Hydralazine

The antihypertensive hydralazine causes anti-MPO-positive antineutrophil cytoplasmic antibody vasculitis, typically after years of therapy and at higher cumulative doses. Presents with glomerulonephritis, arthralgias, and occasionally pulmonary-renal syndrome. Histone-reactive antinuclear antibody (as in drug-induced lupus) may also be present.

Minocycline

Long-term minocycline for acne is associated with MPO-ANCA and drug-induced lupus-like syndrome. Discontinuation typically leads to clinical improvement.

Levamisole-Adulterated Cocaine

As detailed above under false positives, levamisole induces antineutrophil cytoplasmic antibody (anti-PR3 and anti-MPO), agranulocytosis, and vasculitis. This has become increasingly common as levamisole prevalence in the cocaine supply exceeds 70% in North America.

Other Implicated Drugs

Allopurinol, D-penicillamine, carbimazole, clozapine, and rifampicin have been reported in case series. The common final pathway is hapten-induced autoantibody generation or molecular mimicry with MPO.

Back to Table of Contents

Serial Antineutrophil Cytoplasmic Antibody Monitoring for Disease Activity

One of the most clinically debated applications of antineutrophil cytoplasmic antibody testing is serial monitoring to predict relapse in patients in remission. The evidence is stronger for PR3-ANCA than MPO-ANCA:

PR3-ANCA and Relapse Prediction

Multiple prospective studies and the 2014 EUVAS (European Vasculitis Study Group) consensus indicate that a sustained rise in PR3-ANCA titer (typically ≥2-fold increase on two consecutive measurements, or conversion from negative to positive) is associated with an increased risk of relapse within 3–6 months. The positive predictive value of rising PR3-ANCA for relapse is approximately 57–80% depending on the study, meaning a rising titer should prompt clinical assessment and consideration of pre-emptive treatment escalation, but not automatic immunosuppression without clinical symptoms.

MPO-ANCA and Relapse Prediction

Anti-MPO titers are less reliably predictive of relapse than anti-PR3. MPO-ANCA levels may remain elevated in clinical remission without heralding relapse, and some patients relapse without preceding titer rise. Clinical symptoms, urinalysis (hematuria, casts), C-reactive protein (CRP), and creatinine remain essential monitoring tools alongside antineutrophil cytoplasmic antibody titers in MPO-ANCA disease.

Monitoring Protocol

Typical practice: antineutrophil cytoplasmic antibody testing every 3–6 months in remission, more frequently if symptoms emerge. Urinalysis with microscopy at every visit — the kidneys are the organ most vulnerable to subclinical relapse. Chest imaging for respiratory symptoms. Any combination of rising antineutrophil cytoplasmic antibody titer plus new clinical findings (hematuria, creatinine rise, new respiratory symptoms) should be evaluated promptly; immunosuppression should not be pre-emptively escalated based on titer rise alone without clinical correlation.

Back to Table of Contents

Key Research Papers

  1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11. — PubMed PMID: 23045170
  2. Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Revised 2017 International Consensus on Testing of ANCAs in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. Nat Rev Rheumatol. 2017;13(11):683–692. — PubMed PMID: 28905856
  3. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417–427. — PubMed PMID: 23902481
  4. Zwerina J, Eger G, Englbrecht M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum. 2009;39(2):108–115. — Search PubMed
  5. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–1780. — PubMed PMID: 25372085
  6. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232. — PubMed PMID: 20647199
  7. Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum. 2011;63(4):863–864. — Search PubMed
  8. Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol. 2015;26(3):537–542. — Search PubMed
  9. Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004;65(6):2145–2152. — PubMed PMID: 15149327
  10. Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum. 2004;50(9):2954–2965. — Search PubMed
  11. Niles JL, Böttinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996;156(4):440–445. — PubMed PMID: 8607730
  12. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 1998;53(3):743–753. — PubMed PMID: 9507222

PubMed Topic Searches

  1. PubMed: ANCA-associated vasculitis diagnosis and treatment
  2. PubMed: Anti-PR3 and anti-MPO ANCA vasculitis relapse prediction
  3. PubMed: Granulomatosis with polyangiitis ANCA
  4. PubMed: Drug-induced ANCA vasculitis
  5. PubMed: ANCA false positive IBD autoimmune hepatitis

Back to Table of Contents

Connections